Atrial Fibrillation Treatment Market Report by Disorder Type, Treatment Type, End-User, and Region 2024-2032
세계의 심방세동 치료 시장 규모는 2023년에 78억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년 10.3%의 성장률(CAGR)을 보이며, 2032년까지 195억 달러에 달할 것으로 예측하고 있습니다.
심방세동(AFib)은 불규칙하고 빠른 심박수를 동반하는 심장 질환으로 뇌졸중, 심부전 및 기타 심장 관련 합병증의 위험을 증가시킵니다. 이 상태는 심방 상실이 불규칙하게 뛰고 심실 하실과 협동하지 않아 심계항진, 숨가쁨, 피로감을 유발합니다. 또한 혈전 발생으로 이어져 다른 장기로의 혈류를 방해할 수 있습니다. 심방세동의 주요 유형에는 발작성 심방세동, 지속성 심방세동, 장기 지속성 심방세동, 지속성 심방세동이 있으며, 심장의 전기 자극을 조절하는 약물 및 기타 개입을 통해 치료할 수 있습니다.
심혈관 질환(CVDs)의 유병률 증가는 시장 성장을 가속하는 중요한 요인 중 하나입니다. 이러한 질병은 노인 인구와 당뇨병, 고혈압, 심혈관 질환(CVDs)과 같은 다른 질병을 앓고 있는 사람들 사이에서 매우 흔하게 발견됩니다. 이는 전 세계에서 꾸준히 증가하는 노인 인구와 함께 시장 성장을 가속하고 있습니다. 또한 최소침습(MI) 수술에 대한 선호도가 높아지면서 소형 수술 장비, 임플란트 수술, 원격 간호에 대한 수요에 긍정적인 영향을 미치고 있습니다. 손상된 심장 조직을 제거하기 위한 카테터 절제 장비와 혁신적인 매핑 및 기록 시스템 개발 등 다양한 기술 발전도 성장을 가속하는 요인으로 작용하고 있습니다. 이 밖에도 의료 인프라 개선과 의료 과학 분야의 광범위한 조사 개발(R&D) 활동은 시장을 더욱 견인할 것으로 예상됩니다.
이 보고서에서 다룬 주요 질문
- 세계 심방세동 치료제 시장은 지금까지 어떻게 성장했으며, 앞으로 어떻게 성장하는가?
- COVID-19가 전 세계 심방세동 치료 시장에 미치는 영향은?
- 주요 지역 시장은 어디인가?
- 질병 유형별 시장 분석은 무엇인가?
- 치료 유형별 시장 분석은 무엇인가?
- 산업 밸류체인의 다양한 단계는?
- 업계의 주요 촉진요인과 과제는?
- 세계 심방세동 치료 시장의 구조와 주요 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 개요
제4장 서론
제5장 세계의 심방세동 치료 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 질환 유형별
- 발작성 심방세동
- 지속성 심방세동
- 영속성 심방세동
- 기타
제7장 시장 내역 : 치료 유형별
- 의료 시술
- 시장 동향
- 외과 시술
- 비외과용 디바이스
- Electric Cardioversion
- 진단용 카테터
- 지도제작과 기록 시스템
- 심장 모니터
- 액세스 디바이스
- 좌심이 및 폐쇄 디바이스
- 심장 초음파(ICE) 시스템
- 시장 예측
- 의약품
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 바이어의 교섭력
- 공급 기업의 교섭력
- 경쟁의 정도
- 신규 진출업체의 위협
- 대체품의 위협
제13장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업의 개요
- Abbott Laboratories
- Atricure Inc.
- Biotronik
- Boston Scientific Corporation
- Cardiofocus Inc.
- Hansen Medical Inc.(Auris Health)
- Johnson & Johnson
- Siemens Healthineers
- Stereotaxis Inc.
KSA
The global atrial fibrillation treatment market size reached US$ 7.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 19.5 Billion by 2032, exhibiting a growth rate (CAGR) of 10.3% during 2024-2032.
Atrial fibrillation (AFib) refers to a cardiac condition with irregular and rapid heart rate that increases the risks of stroke, heart failure and other heart-related complications. In this condition, the upper (atrial) chambers beat irregularly and out of coordination with the lower (ventricle) chambers of the heart, thereby causing heart palpitations, shortness of breath and fatigue. It can also lead to the development of blood clots that may disrupt the blood flow to other organs. The main types of AFib include paroxysmal, persistent, long-term persistent, and permanent AFib that can be treated with medications and other interventions to adjust the heart's electrical impulses.
The rising prevalence of cardiovascular diseases (CVDs) is one of the key factors driving the growth of the market. Such disorders are highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, hypertension and cardiovascular diseases (CVDs). This, along with the steadily increasing geriatric population across the globe, is providing a boost to the market growth. Furthermore, the increasing preference for minimally invasive (MI) surgical procedures is also creating a positive impact on the demand for miniaturized surgical devices, implant surgeries and remote nursing. Additionally, various technological advancements, such as the development of catheter ablation devices to remove damaged heart tissues and innovative mapping and recording systems, is acting as another growth-inducing factor. Other factors, including improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global atrial fibrillation treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on disorder type, treatment type and end-user.
Breakup by Disorder Type:
Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation
Permanent Atrial Fibrillation
Others
Breakup by Treatment Type:
Medical Procedures
Surgical Procedures
Maze Surgery
Catheter Ablation
Non-Surgical Procedures
Electric Cardioversion
Diagnostic Catheters
Mapping and Recording Systems
Cardiac Monitors
Access Devices
Left Atrial Appendage and Closure Devices
Intracardiac Echocardiography (ICE) Systems
Medication
Anticoagulants
Anti-Arrhythmics
Breakup by End-User:
Hospitals
Cardiac Labs
Ambulatory Surgical Centers
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Atricure Inc., Biotronik, Boston Scientific Corporation, Cardiofocus Inc., Hansen Medical Inc. (Auris Health), Johnson & Johnson, Siemens Healthineers, Stereotaxis Inc., etc.
Key Questions Answered in This Report:
- How has the global atrial fibrillation treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global atrial fibrillation treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the disorder type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global atrial fibrillation treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Atrial Fibrillation Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Disorder Type
- 6.1 Paroxysmal Atrial Fibrillation
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Persistent Atrial Fibrillation
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Permanent Atrial Fibrillation
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Treatment Type
- 7.1 Medical Procedures
- 7.1.1 Market Trends
- 7.1.2 Surgical Procedures
- 7.1.2.1 Maze Surgery
- 7.1.2.2 Catheter Ablation
- 7.1.3 Non-Surgical Devices
- 7.1.3.1 Electric Cardioversion
- 7.1.3.2 Diagnostic Catheters
- 7.1.3.3 Mapping and Recording Systems
- 7.1.3.4 Cardiac Monitors
- 7.1.3.5 Access Devices
- 7.1.3.6 Left Atrial Appendage and Closure Devices
- 7.1.3.7 Intracardiac Echocardiography (ICE) Systems
- 7.1.4 Market Forecast
- 7.2 Medications
- 7.2.1 Market Trends
- 7.2.2 Drug Class
- 7.2.2.1 Anticoagulants
- 7.2.2.2 Anti-Arrhythmics
- 7.2.3 Market Forecast
8 Market Breakup by End-User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Cardiac Labs
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Ambulatory Surgical Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Atricure Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Biotronik
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Boston Scientific Corporation
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 SWOT Analysis
- 13.3.5 Cardiofocus Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.6 Hansen Medical Inc. (Auris Health)
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 Johnson & Johnson
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Siemens Healthineers
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.9 Stereotaxis Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
